spin-off

Johnson & Johnson Stock Today: Q3 Beat, Orthopaedics Spin-Off and New Cancer Data Power a 40% Rally

Johnson & Johnson stock (NYSE: JNJ) has quietly turned into one of 2025’s standout blue‑chip winners. As of December 9, 2025, JNJ trades around $202 per share, valuing the company at roughly $486 billion and leaving the stock up close

9 December 2025

Comcast Stock (CMCSA) Rises as Versant Spin-Off Nears: Latest News, Analyst Targets, and 2026 Outlook

Comcast stock (CMCSA) is trading in the high‑$20s as the company moves ahead with its Versant Media Group spin‑off, digests mixed broadband trends, and faces sharply divided analyst opinions. Here’s the full picture as of December 5, 2025. Comcast stock

5 December 2025

Analyst Insights · Corporate News · Financial Forecasts · Investing · Stock Market

Unilever PLC Stock on 3 December 2025: Magnum Spin‑Off, Graze Sale and Governance Scrutiny Shape the Outlook

Unilever PLC (LSE: ULVR, NYSE: UL) heads into the final stretch of 2025 with its share price pinned in a tight range while the investment story gets noisier: a blockbuster Magnum Ice Cream Company spin‑off, fresh portfolio disposals, regulatory heat

3 December 2025

Business News · Corporate Governance · Investment Analysis · Mergers & Acquisitions · NYSE:UL · Stock Market

Johnson & Johnson Stock (JNJ) Near Record Highs: Earnings Momentum, Spin‑Off Plans and Talc Risks in 2025

Published: November 29, 2025 – This article is for information only and is not financial advice. JNJ stock today: a mega‑cap back in the spotlight Johnson & Johnson stock (NYSE: JNJ) is ending November 2025 right up against its all‑time

29 November 2025

Earnings Reports · Healthcare Sector · Investment Strategies · NYSE:JNJ · Risk Analysis · Stock Market

Johnson & Johnson Stock (JNJ) Near Record Highs: Halda Deal, Spin‑Off Plans and Talc Risks on November 28, 2025

Updated: November 28, 2025 Johnson & Johnson (JNJ) is closing out 2025 as one of the standout “defensive” winners in the U.S. market. The stock is trading just below a fresh 52‑week high around $205–$208 per share, giving the healthcare

28 November 2025

Corporate Strategy · Investment Analysis · Legal Risks · Pharmaceuticals · Stock Market

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

Background: J&J’s Three-Way Split Strategy Johnson & Johnson, a healthcare conglomerate, historically consisted of consumer health, pharmaceutical (Innovative Medicine), and medical technology divisions. In 2023 J&J spun off its consumer products (Tylenol, Band-Aid, Neutrogena, etc.) into a new public company,

14 October 2025

Business News · Corporate Strategy · Healthcare · Industry Trends · Medical Devices · NYSE:JNJ · NYSE:KVUE